50 related articles for article (PubMed ID: 1388772)
1. A quantitative structure-activity relationship for some dopamine D2 antagonists of benzamide type.
Norinder U; Högberg T
Acta Pharm Nord; 1992; 4(2):73-8. PubMed ID: 1388772
[TBL] [Abstract][Full Text] [Related]
2. The development of dopamine D2-receptor selective antagonists.
Högberg T
Drug Des Discov; 1993; 9(3-4):333-50. PubMed ID: 8400011
[TBL] [Abstract][Full Text] [Related]
3. QSAR modeling on dopamine D2 receptor binding affinity of 6-methoxy benzamides.
Samanta S; Debnath B; Gayen S; Ghosh B; Basu A; Srikanth K; Jha T
Farmaco; 2005 Oct; 60(10):818-25. PubMed ID: 16055122
[TBL] [Abstract][Full Text] [Related]
4. GRID/GOLPE 3D quantitative structure-activity relationship study on a set of benzamides and naphthamides, with affinity for the dopamine D3 receptor subtype.
Nilsson J; Wikström H; Smilde A; Glase S; Pugsley T; Cruciani G; Pastor M; Clementi S
J Med Chem; 1997 Mar; 40(6):833-40. PubMed ID: 9083471
[TBL] [Abstract][Full Text] [Related]
5. QSAR prediction of D2 receptor antagonistic activity of 6-methoxy benzamides.
Fatemi MH; Dorostkar F
Eur J Med Chem; 2010 Nov; 45(11):4856-62. PubMed ID: 20728966
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
[TBL] [Abstract][Full Text] [Related]
7. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
8. N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: a potent and selective dopamine D4 ligand.
Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
J Med Chem; 1998 Nov; 41(24):4903-9. PubMed ID: 9822559
[TBL] [Abstract][Full Text] [Related]
9. A 3D QSAR study on a set of dopamine D4 receptor antagonists.
Boström J; Böhm M; Gundertofte K; Klebe G
J Chem Inf Comput Sci; 2003; 43(3):1020-7. PubMed ID: 12767161
[TBL] [Abstract][Full Text] [Related]
10. New benzamide-derived 5-HT3 receptor antagonists which prevent the effects of ethanol on extracellular dopamine, and fail to reduce voluntary alcohol intake in rats.
Iusco G; Boido V; Sparatore F; Colombo G; Saba PL; Rossetti Z; Vaccari A
Farmaco; 1997 Mar; 52(3):141-6. PubMed ID: 9212448
[TBL] [Abstract][Full Text] [Related]
11. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
12. In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors.
Stark D; Piel M; Hübner H; Gmeiner P; Gründer G; Rösch F
Bioorg Med Chem; 2007 Nov; 15(21):6819-29. PubMed ID: 17765546
[TBL] [Abstract][Full Text] [Related]
13. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
Andersen K; Liljefors T; Hyttel J; Perregaard J
J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
[TBL] [Abstract][Full Text] [Related]
14. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ
J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
[TBL] [Abstract][Full Text] [Related]
15. Differentiating dopamine D2 ligands by their sensitivities to modification of the cysteine exposed in the binding-site crevice.
Javitch JA; Fu D; Chen J
Mol Pharmacol; 1996 Apr; 49(4):692-8. PubMed ID: 8609898
[TBL] [Abstract][Full Text] [Related]
16. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms.
Schetz JA; Chu A; Sibley DR
J Pharmacol Exp Ther; 1999 May; 289(2):956-64. PubMed ID: 10215675
[TBL] [Abstract][Full Text] [Related]
17. Solid state conformations and antidopaminergic effects of remoxipride hydrochloride and a closely related salicylamide, FLA 797, in relation to dopamine receptor models.
Högberg T; Rämsby S; de Paulis T; Stensland B; Csöregh I; Wägner A
Mol Pharmacol; 1986 Oct; 30(4):345-51. PubMed ID: 2945089
[TBL] [Abstract][Full Text] [Related]
18. Spiperone: influence of spiro ring substituents on 5-HT2A serotonin receptor binding.
Metwally KA; Dukat M; Egan CT; Smith C; DuPre A; Gauthier CB; Herrick-Davis K; Teitler M; Glennon RA
J Med Chem; 1998 Dec; 41(25):5084-93. PubMed ID: 9836624
[TBL] [Abstract][Full Text] [Related]
19. Conformational analysis of dopamine D-2 receptor antagonists of the benzamide series in relation to a recently proposed D-2 receptor-interaction model.
Pettersson I; Liljefors T
J Med Chem; 1992 Jun; 35(13):2355-63. PubMed ID: 1535660
[TBL] [Abstract][Full Text] [Related]
20. The role of QSAR in dopamine interactions.
Hansch C; Verma RP; Kurup A; Mekapati SB
Bioorg Med Chem Lett; 2005 Apr; 15(8):2149-57. PubMed ID: 15808487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
